BioCryst Presents Results from Its BCX4208 Gout Program at the Annual European Congress of Rheumatology
06:30 EDT 6 Jun 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that additional
safety and efficacy results from its BCX4208
gout program will be presented at the Annual European Congress of
Rheumatology hosted by the Europe...
Other Sources for this Article
Investor Contact
BioCryst Pharmaceuticals
Robert Bennett,
+1-919-859-7910
or
Media Contact
Catherine Collier
Kyroulis, +1-212-301-7174
More From BioPortfolio on "BioCryst Presents Results from Its BCX4208 Gout Program at the Annual European Congress of Rheumatology"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
